Altered Sphingolipid Metabolism in Osimertinib-Resistant Lung Cancer Cells

Julia Babuta's dataset, published on figshare in April 2026, contains multiomics data from a study on drug resistance in non-small-cell lung cancer. The 8.4 MB dataset, stored in XLSX format, combines lipidomics and proteomics analyses of pharmacologically-induced osimertinib-resistant cellular models. It investigates the role of dysregulated sphingolipid metabolism in the development of resistance to the EGFR-TKI drug osimertinib.

Use Cases

• Identify lipidomic signatures associated with drug resistance based on altered sphingolipid metabolism.
• Analyze proteomic changes in osimertinib-resistant cell lines to understand resistance mechanisms.
• Investigate the correlation between ceramide levels and caspase-3 activation in apoptosis pathways.
• Test hypotheses on therapeutic targets by modeling the effect of enzyme inhibitors like D-PDMP on drug sensitivity.

Strengths

• Dataset size is 8.4 MB, indicating a focused multiomics study.
• Data is derived from a multiomics approach combining lipidomics and proteomics analyses.
• The study investigates a specific, clinically relevant mechanism of resistance to the first-line drug osimertinib.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from in vitro cellular models; applicability to in vivo or clinical settings is unknown.

Provenance

Source

Julia Babuta via figshare

Collection Method

Data generated from pharmacologically-induced resistant cellular models using lipidomics and proteomics analyses.

Freshness

Last updated 2026-04-16 09:03:34